Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00062647 · ClinicalTrials.gov registry record · Phase 2
Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia
A Phase 2 study, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00062647 is a Phase 2 study that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 60 participants.
The verdict
NCT00062647, a Phase 2 study, has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections.
Interventions
- DRUG Telavancin
- DRUG Vancomycin, nafcillin, oxacillin, or cloxacillin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2003-08 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00062647
The ClinicalTrials.gov registry entry for NCT00062647 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cumberland Pharmaceuticals, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Telavancin is the first listed.
NCT00062647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00062647 about?
NCT00062647 is a clinical study titled "Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia". The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections.
What is the current status of trial NCT00062647?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2003-08. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00062647?
The interventions under investigation include: Telavancin (DRUG), Vancomycin, nafcillin, oxacillin, or cloxacillin (DRUG).
Who is sponsoring clinical trial NCT00062647?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.